Novo Nordisk And Neose Announce Completion Of Initial Phase 1 Clinical Trial Of NN7128 Long-Acting Factor VIIa
Novo Nordisk A/S (NYSE:NVO) and Neose Technologies, Inc. (Nasdaq GM:NTEC) announced that Novo Nordisk has completed the initial Phase 1 clinical trial with NN7128 (GlycoPEGylated Factor VIIa), a long-acting version of NovoSeven Coagulation Factor FVIIa (Recombinant) administered intravenously.
US Department Of Defense Recommends Soldiers Carry WoundStat trade; For Life-Threatening Bleeding
TraumaCure Inc. announced that the DOD Joint Committee on Tactical Combat Casualty Care (CoTCCC) has recommended that U.S. soldiers from all services carry the company's hemostatic agent, WoundStat™ . The CoTCCC based its recommendations upon the results of extensive studies conducted by both the Army's Institute for Surgical Research (ISR) and the Naval Medical Research Center (NMRC).
Research Shows VASER Ultrasound Assisted Lipoplasty Patients Experience Significantly Lower Blood Loss
Findings from a comparative analysis study of blood loss during lipoplasty procedures shows VASER ultrasound-assisted lipoplasty causes significantly less blood loss when compared to traditional tumescent lipoplasty. Results of the study were presented at the annual meeting of the American Society for Aesthetic Plastic Surgery held the first week of May at the San Diego Convention Center.
AHRQ Announces Guide To Help Patients On Coumadin R Warfarin Therapy
The U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality released a new consumer publication, Your Guide to Coumadin /Warfarin Therapy. This 20-page, easy-to-read patient brochure explains what patients should expect and watch out for while undergoing Coumadin /warfarin therapy.
Hemophilia - Extended Half-Life Recombinant VIIa Leads To Longer Biologic Activity
New data presented at Hemophilia 2008 seen as another step to single dosing regimen of one injection per bleeding event for hemophilia patients with inhibitors CSL Behring presented results of a pre-clinical study that not only demonstrates the feasibility of genetically fusing factor VIIa to human albumin, but that this therapeutic protein with a prolonged half-life can lead to a longer biologic effect.
AdvanDx Submits Yeast Traffic Light PNA FISH TM For FDA 510 k Clearance For Detection Of Candida Species In Positive Blood Cultures
AdvanDx announced the FDA 510(k) submission of Yeast Traffic Light PNA FISH(TM) for detection of Candida yeast species from positive blood cultures. Yeast Traffic Light(TM) is the latest addition to AdvanDx's easy-to-use, molecular-based PNA FISH(TM) diagnostics platform that provides rapid identification of bloodstream pathogens in hours instead of days.
Superiority Of Bivalirudin In Heart Attack Patients At 30 Days Revealed By Landmark Study
The Cardiovascular Research Foundation (CRF) has announced that the New England Journal of Medicine published results of the HORIZONS AMI trial which showed the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduced net adverse clinical events by 24 percent compared to the standard treatment, as well as reduced the risk of overall mortality by 33 percent and cardiac mortality by 38 percent.
EntreMed's ENMD-2076 Demonstrates Antitumor Activity In Multiple Myeloma Model
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of preclinical data for its Aurora A/angiogenesis kinase inhibitor, ENMD-981693, the free base of ENMD-2076.
Blood Donation More Risky For Teenagers
Compared to older blood donors, sixteen and seventeen year olds aremuch more likely to experience complications related to donation, suchas fainting and bruising. This was published in a study in JAMApublished on May 21, 2008. According to the authors, blood donation centers are continuouslychallenged with finding more safe blood as donors dwindle.
Blood Free Monitoring As Good As Blood Tests In Predicting The Course Of AIDS
Researchers at the University of Pennsylvania School of Medicine have shown that monitoring treatment adherence to AIDS therapy is a simple blood-free way to monitor risk of disease progression. The international study was published in the May issue of the journal PLoS Medicine.